Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort
- Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Bernstein, Charles N.; Nugent, Zoann; Targownik, Laura E.; Singh, Harminder; Lix, Lisa M. // Gut;Sep2015, Vol. 64 Issue 9, p1403
Background and aims We aimed to determine the predictors and risk for death among persons with either Crohn's disease (CD) or UC compared with the general population. Methods We used the population-based University of Manitoba IBD Epidemiology Database to calculate HRs and their 95% CIs for...
- Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. // Inflammatory Bowel Disease Monitor;2010, Vol. 11 Issue 2, p84
The article looks into the result of the study which investigates the significant changes of the rate and indication for small-bowel resection presented on the Crohn's disease patients at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania.
- Predicting prognosis in patients with inflammatory bowel disease. // Biomedical Market Newsletter;9/30/2011, Vol. 21, p436
The article offers information on the gene expression profile discovered by researchers that could predict prognosis in patients with Crohn's disease (CD) and ulcerative colitis (UC).
- Cytomegalovirus Pneumonia: A Possible Cause of Death in Patients With Crohn's Disease. Cascio, Antonio; Iaria, Chiara; Fries, Walter // American Journal of Gastroenterology;Mar2013, Vol. 108 Issue 3, p454
A letter to the editor is presented in response to the research paper related to mortality and infection in patients suffering Crohn's Disease (CD) by G.R. Lichtenstein, B.G. Feagan and R.D. Cohen. in a previous issue.
- Consumption of Dental Treatment in Patients with Inflammatory Bowel Disease, a Register Study. Johannsen, Annsofi; Fored, Michael C.; Håkansson, Jan; Ekbom, Anders; Gustafsson, Anders // PLoS ONE;8/12/2015, Vol. 10 Issue 8, p1
Objective: The aim of this study was to compare the consumption of dental treatment among patients with CrohnÂ´s disease (CD) or ulcerative colitis (UC) compared to age and gender matched control groups. Design: The study group comprised 2085 patients with CD and 3161 with UC from the...
- Detection of DNA hypermethylation in sera of patients with Crohn's disease. JIN-HAN BAE; JONGHA PARK; KWANG MO YANG; TAE-OH KIM; JOO MI YI // Molecular Medicine Reports;2014, Vol. 9 Issue 2, p725
Mounting evidence suggests that inflammatory bowel disease (IBD) is caused by genetic predisposition of various genes as well as an abnormal interaction with environmental factors, resulting in epigenetic alterations. It has become evident that epigenetic factors play a significant contributory...
- Immunization status in children with inflammatory bowel disease. Longuet, Romain; Willot, Stephanie; Giniès, Jean-Louis; Pélatan, Cecile; Breton, Estelle; Segura, Jean-François; Bridoux, Laure; Henaff, Gaelle; Cagnard, Benoit; Jobert, Agathe; Cardonna, Joël; Grimal, Isabelle; Balençon, Martine; Darviot, Estelle; Delaperrière, Nadège; Caldari, Dominique; Piloquet, Hugues; Dabadie, Alain // European Journal of Pediatrics;May2014, Vol. 173 Issue 5, p603
Inflammatory bowel diseases have an increased risk of infections due to immunosuppressive therapies. To report the immunization status according to previous recommendations and the reasons explaining a delay, a questionnaire was filled in by the pediatric gastroenterologist, concerning...
- Crohn's disease: why the disparity in mortality? Loftus Jr., E. V. // Gut;Apr2006, Vol. 55 Issue 4, p447
The article comments on a study conducted by F.L. Wolters and colleagues titled "Crohn's Disease: Increased Mortality 10 Years After Diagnosis in a Europe-Wide Population-Based Cohort." The author cites the strengths and weaknesses of the EC-IBD mortality study. He also compares the EC-IBD study...
- Sustained remission in patients with Crohn's disease. // British Journal of Hospital Medicine (17508460);Jul2009, Vol. 70 Issue 7, p377
The article reports on the remission in patients with Crohn's disease to three years of therapy. It mentions that 64 percent of adalimumab-treated patients who were in remission after a year in the CHARM study remains in remission at the end of two additional years in the open label extension....